Radically different
Conner James Black, associate director of the Autism Center at the Child Mind Institute, encourages families to have two separate devices: one for communication and another for entertainment, rather than using one for both.
The post Some parents see a villain in ‘Toy Story 5.’ Others see a lifeline. appeared first on Child Mind Institute.
Laura Sepp-Lorenzino, PhD, is scientific advisor and former chief scientific officer at Intellia Therapeutics, a clinical-stage genome editing company developing potential curative CRISPR-based medicines. Previously, she was vice president and head of Nucleic Acid Therapies at Vertex Pharmaceuticals and part of External Innovation. She also held roles at Alnylam Pharmaceuticals and Merck & Co. In addition, she currently serves as the director of the American Society of Gene and Cell Therapy (ASGCT).
Shengdar Tsai, PhD, is an associate member in the Department of Hematology at St. Jude Children’s Research Hospital. His lab’s research focuses on developing genome editing technologies for therapeutics, with a special interest in editing human HSCs for treatment of hemoglobinopathies such as sickle cell disease and T cells for cancer immunotherapy. In 2020, he was chosen as one of the American Society for Gene and Cell Therapy (ASGCT) Outstanding New Investigators.
Complex biologics such as bifunctional antibodies are opening new therapeutic possibilities in oncology, but these molecules present CRISPR is now a household term. Stories of genome editing therapies like Casgevy and Baby KJ have been headlines in our inboxes for years. Despite those cases, and the optimism they bring, genome editing has had significant challenges moving into the clinic.
This GEN Live show will bring together a panel of leading experts to break down the latest advances, innovations, and challenges shaping genome editing. The discussion will cover a lot of bases: CRISPR breakthroughs, emerging gene editing platforms, clinical trial milestones, regulatory shifts, access, off-target effects and safety considerations, and the growing role of large-scale population genomics in guiding precision therapies. Please join us to learn more and—because we plan to take questions from the audience—please bring your questions for our panelists, too!
Produced with support from:
The post Genome Editing at the Turning Point—Bringing CRISPR to Clinical Reality appeared first on GEN – Genetic Engineering and Biotechnology News.
Researchers at Weill Cornell Medicine and Roswell Park Comprehensive Cancer Center have genetically engineered CAR T cells that specifically target and kill bladder cancer (BCa) cells. Through their preclinical study the team, co-led by Taha Merghoub, PhD, a professor at Weill Cornell Medicine, identified the protein MUC16 as a clinically relevant target for bladder cancer, and demonstrated that direct delivery of MUC16-targeting CAR T cells into the bladder via a catheter can control bladder tumors in mice. The investigators say their study raises hopes that a similar approach may be effective in humans.
The team reported on their results in Journal of Experimental Medicine, in a paper titled “Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models,” concluding that their findings “… not only establish MUC16 as a clinically relevant target for anti-BCa CAR T-cell therapy, but also suggest that intravesical delivery, a commonly used administration route in urological practice, represents a viable, easy-to-implement, and more effective strategy of antitumoral adoptive CAR T-cell transfer.”
Approximately 600,000 new cases of bladder cancer are diagnosed worldwide each year, causing nearly 200,000 deaths, the authors wrote. Treatment generally involves surgical removal of the tumor followed by chemotherapy or immunotherapy. But these approaches are associated with high recurrence and progression rates, often necessitating complete removal of the bladder, a life-altering procedure that can lead to significant complications. “Intravesical therapies are the mainstay of bladder cancer (BCa) management, but their efficacy is limited by toxicities and recurrences,” they continued. “Given these challenges there is a significant unmet clinical need, driving renewed interest in bladder-sparing therapies for patients with high-risk bladder cancer who are unfit or unwilling to have their bladder removed,” Merghoub said.
CAR T cells are immune cells genetically engineered to express an artificial receptor protein capable of specifically targeting cancer cells. This type of immunotherapy has been successfully used to treat many different types of blood cancer. But success against solid tumors has so far been limited due to challenges that include poor tumor infiltration and off-target toxicity. Merghoub and colleagues attempted to overcome these issues by creating CAR T cells with high specificity for bladder cancer cells and then delivering them directly to the bladder via a catheter, known as intravesical delivery.
The team developed an antigen discovery pipeline, through which they identified MUC16 as a promising BCa target. “In this study, we leveraged a computational antigen-identification pipeline, which prioritized high tumor specificity and minimal pan-tissue expression to rationally identify MUC16 as a potential target for BCa-directed CAR T-cell therapy,” they stated. The researchers also noted that MUC16 and its soluble form, CA-125, have previously been identified as prognostic biomarkers for BCa, and MUC16 has been investigated as a CAR T-cell therapy target in other malignancies, and particularly ovarian cancer.
Through their newly reported study the investigators found that MUC16 is highly expressed on the surface of many bladder cancer cells, including types that are resistant to existing therapies, but is largely absent from normal bladder cells and other healthy tissues. “Given its favorable expression profile, absence in normal bladder, and high expression across a broad spectrum of bladder tumors analyzed collectively spanning a total of 1,292 patients, including those recalcitrant to existing therapies, MUC16 was selected as the lead candidate for BCa-specific CAR T-cell therapy development,” they wrote.
The researchers then generated CAR T cells that target MUC16. In initial tests these CAR T cells were able to kill MUC16-positive tumors grown in the lab from patient-derived bladder cancer cells. Merghoub and colleagues then tested the ability of the MUC16-targeting CAR T cells to control the growth of human bladder cancer cells implanted in the bladders of mice. The team found that the CAR T cells were ineffective when administered intravenously, but when delivered intravesically, they reduced tumor growth and extended survival. When administered directly into the bladder, the CAR T cells were unable to spread into the rest of the body, minimizing the risk of any side effects in other tissues. “Intravesical delivery of these CAR T cells reduced the growth of BCa xenografts and prolonged survival in xenograft-bearing mice, showing superior efficacy compared with typical systemic CAR T-cell administration,” the investigators noted.
“Development of engineered T cells for solid tumors has been challenging, in part due to normal tissue expression of potential target antigens,” Wolchok says. “Using a compartmentalized delivery system allows us to overcome this hurdle and hopefully come one step closer to broader use of CAR and transgenic T cells for common solid tumors, like bladder cancer.”
“Our findings establish MUC16 as a clinically relevant target for CAR T-cell therapy in bladder cancer, and highlight that intravesical delivery, a commonly used administration route in urological practice, represents a feasible, effective, and readily easy-to-implement strategy for adoptive CAR T-cell transfer,” Merghoub said. “This approach could be useful for both initial treatment of bladder cancer as well as treatment refractory subsets of tumors, offering an attractive therapeutic option for patients who may have limited therapeutic alternatives besides bladder removal.”
In their paper the team also suggest that their findings “… lay the groundwork for refining CAR T-cell therapies targeting other antigens for BCa.”
The post Intravesical CAR T-Cell Therapy Reduces Bladder Cancer Growth in Preclinical Model appeared first on GEN – Genetic Engineering and Biotechnology News.
Nipah virus—and the closely related Hendra virus—are zoonotic pathogens causing severe respiratory and neurological disease with high mortality rates. Outbreaks are rare but often devastating, with mortality rates ranging from 40 to 75 percent. There are no approved human vaccines or therapeutics for people infected with these viruses.
Now, an international research team led by investigators at the Icahn School of Medicine at Mount Sinai has developed the first fully human monoclonal antibody cocktail shown to provide complete protection against Nipah and Hendra virus infection—even when treatment was given after infection had begun. The findings represent an important step toward developing the first antibody-based therapy for Nipah virus and establish a promising strategy for combating emerging infectious diseases.
This work is published in Science Translational Medicine, in the paper, “A cocktail of human mAbs targeting the henipavirus fusion and receptor binding proteins provides cross-species neutralization.”
“One of the biggest challenges in developing treatments for henipaviruses is that human survivor samples are extremely rare,” said Axel Guzman-Solis, a graduate student in the Department of Microbiology at the Icahn School of Medicine. “We wanted to determine whether we could create fully human antibodies that target the virus in multiple ways at once, making it much more difficult for the virus to evolve resistance.”
The researchers used vaccinated humanized mice with the fusion protein (F) and receptor binding protein (RBP) of Nipah virus with the goal of isolating monoclonal antibodies. The investigators discovered two antibodies, 8G3 and 2A1, which targeted the RBP and F proteins, respectively, and together, could neutralize the virus and limit the potential for immune escape. Because the antibodies work through independent mechanisms, they create multiple barriers to infection and make it more difficult for the virus to develop resistance.
Using cryo-EM, the researchers discovered that the 2A1 antibody neutralizes the virus by stabilizing a sugar-containing structure on the viral fusion protein rather than displacing it, as scientists had anticipated. This previously unrecognized strategy may help explain the antibody’s potency and resilience against viral escape.
“We were surprised to find that the antibody essentially embraces a structure on the virus that many antibodies try to move out of the way,” said Benhur Lee, MD, chair in microbiology at the Icahn School of Medicine. “The finding suggests that stabilizing a viral protein can sometimes be just as effective—or even more effective—than disrupting it.”
When administered together, the antibody cocktail completely protected hamsters from lethal Nipah virus infection. The treatment remained effective even after infection was established, an encouraging result for a disease that progresses rapidly and carries a high fatality rate.
The findings may have broader implications for pandemic preparedness. Because many viruses rely on multiple proteins to infect cells, the researchers believe this dual-targeting strategy could be adapted for other high-priority pathogens.
“This work provides a blueprint for developing antibody therapies that are more resistant to viral evolution,” said Lee. “Rather than relying on a single target, we can attack a virus at multiple vulnerable points simultaneously.”
Next steps include studies in nonhuman primates, evaluation of long-term safety, and efforts to optimize the antibodies for clinical use. The team is also exploring next-generation antibody formats, including single molecules capable of targeting multiple viral proteins simultaneously, as well as approaches that could broaden protection against additional members of the henipavirus family.
“As zoonotic outbreaks continue to emerge around the world, there is an urgent need for therapies that can be deployed quickly against high-consequence pathogens,” said Lee. “Our long-term goal is to translate these discoveries into practical tools that help protect people during future outbreaks.”
The post Nipah and Hendra Viruses: Antibody Cocktail Provides Complete Protection in Hamster Model appeared first on GEN – Genetic Engineering and Biotechnology News.
A first-in-human clinical trial of an experimental epigenetic therapy has produced an outcome long considered elusive in the progressive genetic muscle degeneration disease facioscapulohumeral muscular dystrophy (FSHD): measurable gains in lean muscle volume.
Epicrispr Biotechnologies announced updated interim results from its ongoing Phase I/II study of EPI-321, reporting that all three FSHD patients who reached the six-month evaluation point experienced increases in lean muscle mass following a single intravenous (IV) infusion of the therapy. The findings represent what the company says is the first clinical evidence that a treatment may be capable of increasing muscle volume in FSHD, which affects an estimated 870,000 people worldwide and is one of the most common forms of muscular dystrophy.
Although the study remains in its early stages with only nine total patients across two dosing cohorts, the promising findings were supported by imaging data, functional measurements, and biomarker changes that together suggest the therapy may be altering the biological drivers of the disease.
FSHD lacks disease-modifying treatments to intervene in the characteristic loss of skeletal muscle function, starting in the face, shoulders, and upper arms and spreading throughout the body. “We were pretty blown away,” Epicrispr CEO Amber Salzman told Inside Precision Medicine. “Every single patient gained lean muscle volume. No one has seen that.”
FSHD is caused by hypomethylation of the D4Z4 region, which is a polymorphic variable number tandem repeat (VNTR) array made up of 3.3 kilobase units, with each unit encoding the DUX4 gene. This hypomethylation leads to abnormal activation of the DUX4 gene, triggering muscle cell death and tissue degeneration, resulting in progressive muscle weakness, asymmetry, and fat infiltration.
Unlike conventional gene-editing therapies that permanently alter DNA sequences, Epicrispr’s therapy uses their Gene Expression Modulation System (GEMS). Epicrispr’s EPI-321 is an adeno-associated virus (AAV)-delivered epigenetic gene therapy that restores D4Z4 methylation and suppresses DUX4 expression, and preclinical studies show improved muscle function and reduced muscle cell death. “We don’t cut DNA,” Salzman said. “We’re not using Cas9 in the traditional editing sense. We use a dead Cas protein and an epigenetic mechanism to silence the gene.”
According to Epicrispr, preclinical studies demonstrated that the epigenetic modifications persist through many rounds of cell division, suggesting long-term suppression may be possible after a single treatment.
In addition to the therapeutic innovation, Epicrispr has also made headway into the long-standing challenge of identifying reliable molecular biomarkers for FSHD to evaluate activity downstream of DUX4. Traditional muscle biopsies provide information from only a small tissue sample and can be difficult to interpret when substantial fat replacement has already occurred.
Instead, Epicrispr collaborated with researchers at the University of Colorado investigating circulating cell-free DNA signatures associated with DUX4-driven disease activity. The biomarker, known as CBT17, emerged from studies comparing blood samples from approximately 50 healthy individuals and 50 FSHD patients. The biomarker may provide a whole-body readout of disease activity, offering evidence that DUX4 suppression is occurring beyond individual muscles examined through biopsy.
As of the May 12, 2026 data cutoff, EPI-321 has demonstrated a manageable safety profile, with nine patients treated across two dose cohorts. One IV infusion was administered to six patients in the first cohort at a target dose of 2×10¹³ vg/kg and to three patients in the second cohort at a target dose of 4×10¹³ vg/kg.
The company reported a “manageable” safety profile, with no severe dose-limiting toxicities disclosed to date. Salzman was careful not to overstate the findings. “I never want to be hubristic when it comes to AAV,” she said. “You’re giving people a lot of virus.”
She described the treatment experience as somewhat analogous to vaccine-related immune responses, noting that prophylactic immunosuppression is used as part of the protocol. “It’s manageable,” she said. “I’m not going to say it’s favorable. It’s manageable.” No serious grade 3 or grade 4 treatment-related safety concerns have been reported so far.
Baseline levels of CBT17 in treated patients fell substantially after therapy. “When we looked at baseline and three months, our patients’ levels came down so that it was just about in the healthy range,” she said.
The headline result comes from whole-body MRI analyses conducted six months after treatment. Among the first three evaluable patients, lean muscle volume increased in every individual compared with baseline measurements. On average, patients gained approximately 370 milliliters of lean muscle tissue, equivalent to roughly 0.8 pounds of muscle mass. Individual gains ranged from about 0.5 to 1.3 pounds. For a disease characterized by chronic muscle loss, even stabilizing muscle mass would be considered a meaningful achievement. Actual gains are potentially more significant.
The MRI analyses were performed in collaboration with Springbok Analytics, a company specializing in AI-powered muscle imaging. In addition to being widely used in professional sports to monitor injury recovery and rehabilitation, as well as a growing number of clinical settings, FSHD is one of Springbok’s primary clinical focus areas, along with disorders such as Charcot-Marie-Tooth disease and Duchenne muscular dystrophy. Using a specialized MRI protocol that runs on standard scanners, the company can quantify changes across as many as 140 individual muscles throughout the body, measuring muscle volume, muscle composition, and fat infiltration, producing objective data on muscle health.
According to Salzman, Springbok compared patients’ baseline scans against machine-learning models trained on longitudinal imaging datasets from more than 100 FSHD patients. “They can predict what it’s going to look like in six months—how much muscle patients will lose and where,” she said. “Then we sent them the six-month scans, and every patient gained lean muscle volume.”
The gains were not evenly distributed throughout the body. Patients appeared to benefit most in muscles that still retained substantial healthy tissue before treatment. “If you have too much fat in that muscle, there’s not that much we can do,” Salzman explained. “But if you have some residual muscle, it can not only stop getting worse because we’re cutting off the poison, but you can also regenerate muscle.”
One participant, a post-menopausal woman, gained approximately 1.3 pounds of lean muscle mass according to the MRI analysis. The increase was particularly notable because age-related muscle loss would normally be expected in that population. Earlier data released by Epicrispr showed favorable trends across several functional and strength assessments at the three-month mark. These measures included tests commonly used in neuromuscular disease studies, such as the Timed Up and Go test, 10-meter walk/run assessments, and quantitative muscle testing.
Because many functional endpoints depend on patient effort, interpreting changes in small open-label studies can be challenging. Investigators and investors alike often question whether participants simply perform better because they know they received treatment. Salzman acknowledged those concerns. “You could say maybe they had a good day, and that’s why the functional measures were better,” she said.
MRI measurements, however, are not subject to effort-dependent variability. “You can’t fake MRI,” she added. Importantly, the regions showing muscle growth on imaging appeared to correspond with areas where patients demonstrated improved performance.
One participant who gained substantial upper-body muscle volume showed corresponding gains on upper-body strength assessments, while lower-body improvements were more limited in areas where muscle loss had already become severe. “The whole story is holding together,” Salzman said. “Their functional measures are getting better; their lean muscle is increasing.”
Taken together, the MRI, biomarker, and functional data provide multiple independent signals supporting biological activity. “You can’t fake blood; you can’t fake MRIs,” Salzman said. “Those are totally supportive.”
Beyond FSHD, researchers are closely watching EPI-321 because it represents one of the first clinical tests of an epigenetic CRISPR-based therapeutic strategy. “This is an important milestone not just for FSHD but for epigenetic medicine,” Salzman said. The approach could potentially be adapted to other diseases caused by harmful gene activation or insufficient gene silencing.
Still, significant hurdles remain before EPI-321 can be considered a proven therapy. The current dataset includes only three patients with six months of follow-up. Epicrispr plans to present additional data from six patients at the World Muscle Society Annual Congress in September 2026.
The company expects the initial Phase I/II study to complete enrollment and generate a full readout in mid-2027. Yet, larger studies will be needed to determine whether muscle gains persist, whether they translate into meaningful long-term functional benefits, and whether safety remains acceptable over time.
Regulators will also require evidence linking increases in lean muscle volume to tangible improvements in patient function and quality of life. To that end, Epicrispr is preparing discussions with the U.S. Food and Drug Administration regarding potential future endpoints and whether MRI-based muscle measurements could eventually serve as surrogate markers of clinical benefit.
Whether those early signals hold up in larger populations remains to be seen. But for a disease in which muscle loss has long been viewed as inevitable, the possibility of reversing that trend, even modestly, marks a notable moment for the FSHD field.
The post Pump You Up: Epigenetic Editor Drives Muscle Growth in FSHD Patients appeared first on Inside Precision Medicine.
By Florencia Assaneo, PhD, Research Fellow, Stavros Niarchos Foundation (SNF) Global Center for Child and Adolescent Mental Health at the Child Mind Institute
Primary education in Latin America has faced a steady decline over recent decades, contributing to what many organizations now describe as an educational crisis. International institutions such as the Economic Commission for Latin America and the Caribbean (ECLAC), the United Nations Educational, Scientific and Cultural Organization (UNESCO), as well as the World Bank Group have all called for urgent action to address worsening learning outcomes across the region. The situation is particularly concerning in Mexico. Results from the 2022 Programme for International Student Assessment showed that Mexico scored well below the Organization for Economic Co-operation and Development (OECD) average in reading, mathematics, and science — placing the country among the lower-performing educational systems evaluated globally.
The consequences of this crisis extend far beyond the classroom. Educational difficulties during childhood are closely linked to long-term social and mental health outcomes. Research has shown that additional years of basic education are associated with lower rates of depression and anxiety (Kondirolli & Sunder, 2022), as well as higher levels of resilience and perceived control over one’s life (Niemeyer et al. 2019). In this sense, poor academic performance in primary school can have lasting effects that continue into adulthood, limiting employment opportunities, increasing vulnerability, and negatively affecting overall well-being.
Open-access interventions that strengthen children’s cognitive and academic abilities could have enormous value in low- and middle-income countries, where educational resources are often limited. Our work explores whether the ability to coordinate movements with rhythmic sounds — such as clapping, tapping, or dancing to music — can be leveraged to support children’s learning and cognitive development through engaging digital tools.
Over the last decade, multiple studies have shown that children who are better at synchronizing their movements to rhythm also tend to perform better on a wide range of cognitive and language-related tasks. These include reading, phonological awareness, processing speed, rapid naming, and other foundational abilities linked to academic success. Researchers have assessed these rhythmic coordination skills in multiple ways, from walking to the beat of music to tapping along with a steady rhythm or coordinating movements while playing musical instruments. Across these different approaches, one result consistently emerges: children who are better at aligning movement with sound also tend to show stronger cognitive performance.
Building on these study findings, my current fellowship project, supported by the Stavros Niarchos Foundation (SNF) Global Center for Child and Adolescent Mental Health at the Child Mind Institute, seeks to better understand how these rhythm synchronization abilities develop during childhood and whether they could eventually be strengthened through interactive digital interventions. Specifically, we are studying the developmental stage at which these abilities become established in children, and whether individuals with stronger rhythmic coordination also show advantages in attention and language-related skills. Understanding when these abilities emerge is particularly important because it may help identify the developmental window during which they are most malleable and therefore most responsive to training or intervention.
In parallel, we are using functional magnetic resonance imaging (fMRI) — a non-invasive brain imaging technique that allows us to observe which brain regions become active during different tasks — to explore the relationship between rhythmic synchronization and the brain’s reward system. Importantly, these same reward-related regions are also strongly engaged during video game play. If the pathways within this reward system are similarly activated during rhythmic coordination, this could mean that children who initially struggle to synchronize movements with sound may be able to strengthen these abilities through a carefully designed video game experience. One possible future application could involve an open-access mobile game in which children synchronize taps or hand movements to musical rhythms while progressing through increasingly challenging levels and unlocking rewards or visual customizations.
Overall, the current project seeks to generate the scientific evidence necessary to determine whether rhythm-based digital interventions could become a viable tool for supporting children’s cognitive development. This work has the potential to contribute to the future development of accessible and scalable tools that can strengthen foundational cognitive skills linked to academic performance in children. These tools can be applied to children in Mexico and, more broadly, across low- and middle-income countries (LMICs), expanding access to education resources and interventions.
Our laboratory at Universidad Nacional Autónoma de México (UNAM) is primarily dedicated to basic neuroscience research. Based at UNAM’s campus in Querétaro, our team brings together researchers and students from different disciplines — including neuroscience, psychology, physics, engineering, and data analysis — united by a shared interest in understanding how rhythm and brain dynamics shape human cognition and behavior. Here, we have access to excellent infrastructure for fundamental research, including neuroimaging facilities and high-performance computational resources. However, translating basic scientific discoveries into interventions capable of improving people’s daily lives is often much more challenging and requires strong cross-sector collaboration.
The work I’m conducting as part of the SNF Global Center Research Fellowship has encouraged us to begin thinking beyond the laboratory. This current fellowship has given us the opportunity to test the core scientific assumptions behind our proposed open-access intervention. If the pilot project proves successful, the next stages of the work will become considerably more ambitious, involving both the technological development of the intervention and its large-scale implementation and evaluation in school settings. Advancing toward those goals will likely require the support of larger international organizations and cross-sector collaborations. In this context, the opportunities provided by the SNF Global Center at the Child Mind Institute to share, disseminate, and give visibility to our work are extremely valuable, helping create the connections and momentum necessary to move from foundational research toward real-world impact.
More broadly, this kind of collaboration highlights the importance of building bridges between global institutions and local research communities. By combining international support with local expertise and close engagement with schools and communities, it becomes possible to develop solutions that are both scientifically rigorous and genuinely connected to the realities of the populations they aim to serve.
Learn more about the Research Fellowship
The post Rhythm-Based Video Games: Exploring the Cognitive and Learning Potential appeared first on Child Mind Institute.
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.
—Jessica Hamzelou
It’s been hot in London this week. Really hot. A dangerous heat wave has hit Western Europe. On Wednesday, the UK recorded its highest ever June temperature at 36.1 °C (about 97 °F). But as the weather app on my phone confirmed, it felt like 39 °C.
Much of Western Europe is suffering, bringing awful consequences for agriculture, infrastructure, and the health system. But heat can also affect the brain.
Studies have confirmed that as temperatures rise, people seem to get more irritable and more violent. And they have shown that firefighters find it harder to focus immediately after heat exposure. Rising temperatures can also have particularly disastrous outcomes for children and people with mental health disorders.
Research on lab animals suggests that excessive heat can alter the function of chemical signals in our brains. But we still need a better understanding of the mechanisms behind these effects.
Here’s what scientists are learning about extreme heat’s impact on the brain.
This story is from The Checkup, our weekly biotech newsletter. Sign up to receive it in your inbox every Thursday.
For more on Europe’s heat wave, read our stories on why soaring temperatures are shutting down power plants and what they mean for the grid.
The must-reads
I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology.
1 The Trump administration has asked OpenAI to limit its next model release
It wants to vet the first GPT 5.6 users before a wider launch. (Bloomberg $)
+ OpenAI said each of the initial partners will be government-approved. (FT $)
+ It’s the first US firm to be told to restrict an AI model before release. (Axios)
+ Anthropic is also still feuding with Washington. (MIT Technology Review)
2 Apple and Xbox have hiked prices, blaming AI-driven chip costs
Some MacBooks, iPads, and Xboxes are going up in price by over 20%. (BBC)
+ Apple’s shares plummeted after the announcement. (NBC)
+ AI data center demand has pushed up memory and storage prices. (WSJ $)
+ The shortages have been dubbed “RAMaggedon.” (The Verge)
3 Colossal and the US are building an endangered species “biovault”
It aims to cryptopreserve over 2,300 plant and animal samples. (Wired $)
+ It comes amid growing threats to endangered species protections. (NYT $)
+ Colossal is also growing chickens in artificial eggshells. (MIT Technology Review)
4 The US has banned Polestar from selling its EVs due to anti-China rules
The Sweden-based company is majority-owned by China’s Geely. (CNN)
+ The ban is because its connected-vehicle tech is linked to China. (Reuters $)
+ What happened to China’s overseas EV factory boom? (Rest of World)
5 China is betting on humanoids to beat its demographic decline
It wants the robots to narrow the labour gap. (FT $)
+ Gig workers are training humanoids at home. (MIT Technology Review)
6 The “fingerprints” of a black hole’s event horizon have been detected
The discovery was made by studying ripples in space-time. (AFP)
7 OpenAI is now expected to delay its IPO until next year
It’s been spooked by choppy global markets and SpaceX’s slump. (NYT $)
8 Data centers have moved to the forefront of environmental lawsuits
The litigation is linked to energy sources, water consumption, and air pollution. (Guardian)
9 A master gene that turns on human development has been uncovered
It results in cells forming a human body. (New Scientist $)
10 Grok’s most popular feature? Smut
It accounts for “well over half” of the chatbot’s traffic. (The Information $)
Quote of the day
—Nathan Benaich, AI investor at London-based venture firm Air Street Capital, tells the Financial Times about the geopolitical reality of US AI dominance.
One More Thing
In 1991, construction workers in Manhattan unearthed hundreds of coffins. Further investigation revealed that the remains were between 200 and 300 years old, and they were all African and African American.
This discovery came at an inflection point in scientific history. Breakthroughs in chemical and genetic analysis allowed researchers to figure out where many of these people were born, the physical challenges they faced, and even the routes they took from Africa to North America.
Today, archaeologists are using techniques they could only dream of then: lasers, 3D photography, lidar, satellite imagery, and more. These tools are revealing where people came from, how ancient cities were built, and the lives of those who built them.
Read the full story on how archaeology is changing our understanding of the past.
—Annalee Newitz
We can still have nice things
A place for comfort, fun, and distraction to brighten up your day. (Got any ideas? Drop me a line.)
+ Tantalise your taste buds with this culinary tour of the planet’s rarest fruits.
+ This Daft Punk and Justice mashup is the French EDM collab that fans never got.
+ Daredevils have delightfully transformed playground equipment into a series of terrifying oversized rides.
+ The gadget department of your childhood dreams comes to life in this rocket-powered pen disguised as a spy weapon.
Top image credit: Sarah Rogers/MITTR | Photos Getty
Please send your childhood dreams to hi@technologyreview.com.
You can follow me on LinkedIn. Thanks for reading!
—Thomas